Skip to main content
. 2019 Jun 7;317(2):H395–H404. doi: 10.1152/ajpheart.00430.2018

Fig. 3.

Fig. 3.

Summary of potential therapeutic targets and contributing mediators of reduced NO bioavailability and endothelial dysfunction during the menopause transition. BH4, tetrahydrobiopterin; ER, estrogen receptor; NO, nitric oxide; ROS, reactive oxygen species.